Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

20143,005 citationsJournal Articlebronze Open Access

Authors

Tomasz M. Beer · Oregon Health & Science University

Andrew J. Armstrong · Duke Medical Center

Dana E. Rathkopf · Memorial Sloan Kettering Cancer Center

Yohann Loriot · Institut Gustave Roussy

Cora N. Sternberg · Nini Hospital

Celestia S. Higano · Seattle Cancer Care Alliance

Peter Iversen

Abstract

Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. (Funded by Medivation and Astellas Pharma; PREVAIL ClinicalTrials.gov number, NCT01212991.).

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Cancer-related Molecular Pathways

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 5, pp. 424-433

DOI: 10.1056/nejmoa1405095

Field-Weighted Citation Impact: 216.26

Command Palette

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Authors

Abstract

Topics & Keywords

Publication Details